Nurix Therapeutics Inc [NRIX] stock is trading at $11.9, down -0.67%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The NRIX shares have gain 14.20% over the last week, with a monthly amount glided 28.23%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Nurix Therapeutics Inc [NASDAQ: NRIX] stock has seen the most recent analyst activity on October 21, 2025, when Mizuho initiated its Outperform rating and assigned the stock a price target of $24. Previously, Leerink Partners started tracking the stock with Market Perform rating on March 17, 2025, and set its price target to $16. On December 10, 2024, BTIG Research initiated with a Buy rating and assigned a price target of $35 on the stock. BMO Capital Markets started tracking the stock assigning a Outperform rating and suggested a price target of $35 on December 06, 2024. UBS initiated its recommendation with a Buy and recommended $35 as its price target on October 24, 2024. Jefferies started tracking with a Buy rating for this stock on October 11, 2024, and assigned it a price target of $41.
Nurix Therapeutics Inc [NRIX] stock has fluctuated between $8.18 and $29.56 over the past year. Currently, Wall Street analysts expect the stock to reach $26.75 within the next 12 months. Nurix Therapeutics Inc [NASDAQ: NRIX] shares were valued at $11.9 at the most recent close of the market. An investor can expect a potential return of 124.79% based on the average NRIX price forecast.
Analyzing the NRIX fundamentals
Nurix Therapeutics Inc [NASDAQ:NRIX] reported sales of 83.69M for the trailing twelve months, which represents a drop of -37.29%. Gross Profit Margin for this corporation currently stands at 0.94% with Operating Profit Margin at -3.19%, Pretax Profit Margin comes in at -2.92%, and Net Profit Margin reading is -2.93%. To continue investigating profitability, this company’s Return on Assets is posted at -0.47, Equity is -0.54 and Total Capital is -0.61. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.15.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.60 points at the first support level, and at 11.29 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.33, and for the 2nd resistance point, it is at 12.75.
Ratios To Look Out For
For context, Nurix Therapeutics Inc’s Current Ratio is 5.35. In addition, the Quick Ratio stands at 5.35 and the Cash Ratio stands at 0.95. Considering the valuation of this stock, the price to sales ratio is 14.41, the price to book ratio is 2.46.
Transactions by insiders
Recent insider trading involved van Houte Hans, Chief Financial Officer, that happened on Aug 01 ’25 when 5402.0 shares were sold. Officer, JOHANNES VAN HOUTE completed a deal on Aug 01 ’25 to buy 5402.0 shares. Meanwhile, Chief Financial Officer van Houte Hans sold 4304.0 shares on Jul 30 ’25.
